CLEC9A Recombinant Monoclonal Antibody

Code: CSB-RA740922MA1HU

Rate （N/A）
Review （0）

Size:

50μl100μl

US$210

Quantity:

Species Reactivity: Human

Application: ELISA

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

Q6UXN8

Target Names

CLEC9A

Alternative Names

C type lectin domain family 9; member A antibody; C-type lectin domain family 9 member A antibody; CLC9A_HUMAN antibody; CLEC9A antibody; DNGR1 antibody; HEEE9341 antibody; PRO34046 antibody; UNQ9341 antibody

Species Reactivity

Human

Immunogen

Recombinant Human CLEC9A protein

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

hIgG4(S228P)

Clone No.

9H7

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form

Liquid
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Tested Applications

ELISA

Recommended Dilution

Application	Recommended Dilution
ELISA	1:5000-1:50000

Protocols

ELISA Protocol

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Datasheet & COA

Antibody FAQs

Images

The Binding Activity of Human CLEC9A with Anti-CLEC9A recombinant antibody
Activity: Measured by its binding ability in a functional ELISA. Immobilized Anti-CLEC9A recombinant antibody at 2 μg/mL can bind Human CLEC9A protein (CSB-MP740922HU-B). The EC₅₀ is 2.915-3.520 ng/mL.

Description

CLEC9A, also known as DNGR-1, is a C-type lectin receptor expressed predominantly on a specialized subset of dendritic cells, where it plays a critical role in sensing damaged cells and orchestrating cross-presentation of dead cell-associated antigens. This function positions CLEC9A at the intersection of innate immunity and adaptive immune responses, making it a compelling target for researchers investigating dendritic cell biology, tumor immunology, and vaccine development strategies that aim to harness cross-presentation pathways.

This recombinant monoclonal antibody, clone 9H7, offers the reproducibility and molecular definition that demanding immunological studies require. Because the antibody sequence is fixed and production occurs in controlled recombinant systems, researchers can expect consistent performance across experiments and between lots, eliminating a common source of variability that can complicate longitudinal studies or multi-site collaborations. The human IgG4 isotype with the S228P stabilizing mutation provides a well-characterized framework suitable for functional assays where Fc-mediated effects need to be minimized or controlled.

Validation data demonstrate robust binding activity in functional ELISA, with immobilized antibody at 2 μg/mL binding recombinant human CLEC9A protein with an EC50 in the low nanogram per milliliter range, specifically 2.915 to 3.520 ng/mL. This high-affinity interaction supports reliable detection across a broad working dilution range of 1:5000 to 1:50000, offering flexibility to optimize signal-to-background ratios for different experimental setups.

For investigators exploring dendritic cell subset identification, cross-presentation mechanisms, or stem cell differentiation pathways involving immune cell lineages, this antibody provides a dependable tool backed by quantitative binding characterization.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

Functions as an endocytic receptor on a small subset of myeloid cells specialized for the uptake and processing of material from dead cells. Recognizes filamentous form of actin in association with particular actin-binding domains of cytoskeletal proteins, including spectrin, exposed when cell membranes are damaged, and mediate the cross-presentation of dead-cell associated antigens in a Syk-dependent manner.

Gene References into Functions

Clec9a is responsible for the antigen cross-presentation of dendritic cell subsets and may be a target of immunotherapy PMID:27250027
findings demonstrate that CLEC9A is a specialized receptor that modulates the innate immune response when there is a mycobacterial infection PMID:29065139
Data indicate that blood dendritic cell antigen 3 BDCA3(+) and C-type lectin domain family 9, member A CLEC9A(+) dendritic cells (DC) are of major importance in the induction of anti-viral and anti-tumor immunity. PMID:24910448
Activated dendritic cell subsets expressing CD141/CLEA9A/CD1c, likely recruited into the tubulointerstitium, are positioned to play a role in the development of fibrosis and, thus, progression to chronic kidney disease. PMID:24049150
study showsn that the DNGR-1 ligand is preserved from yeast to man and corresponds to the F-actin component of the cellular cytoskeleton; identification of F-actin as a DNGR-1 ligand suggests that cytoskeletal exposure is a universal sign of cell damage that can be targeted by the innate immune system to initiate immunity PMID:22483800
High expression of DNGR-1 specifically and universally identifies a unique dendritic cells subset in mouse and humans. PMID:22442345
propose that Clec9A provides targeted recruitment of the adaptive immune system during infection and can also be utilized to enhance immune responses generated by vaccines. PMID:22483802
Data show that CLEC9A is only expressed on immature BDCA3(+) myeloid dendritic cells (mDCs). PMID:22234694
For production of cytotoxic T cells, transgenic DEC-205 and Clec9A, but not Clec12A, are effective targets for antibody-mediated delivery of antigens for vaccination, although only in the presence of adjuvants. PMID:21677141
A population of human dendritic cells (DC) that expresses DNGR-1 (CLEC9A) and high levels of BDCA3 and resembles mouse CD8alpha+ DCs in phenotype and function, is characterized. PMID:20479117
DC, NK lectin group receptor-1 (DNGR-1) is a C-type lectin of the NK cell receptor group PMID:18497879
CLEC9A functions as an activation receptor PMID:18408006
analysis of differences between mouse and human Clec9A PMID:18669894
CLEC9A functions as a SYK-coupled C-type lectin receptor to mediate sensing of necrosis by the principal dendritic-cell subset involved in regulating cross-priming to cell-associated antigens PMID:19219027
The paper cited (J Clin Invest. 2008 Jun;118(6):2098-110) is the first characterization of human and mouse CLEC9A (a.k.a DNGR-1) PMID:18497879